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A B S T R A C T
Aim: To assess the medium term outcomes of Acrysof® toric intraocular lens implantation 
in 54 patients (54 eyes).
Methods: Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), preoperative 
astigmatism, residual postoperative astigmatism, and global average and model-specific 
intraocular lens (IOL) rotation grade were analyzed.
Results: At 2-months of follow-up,the mean UCVA was 0.83 (SD: 0.14) Snellen scale, with 
73.9% of the patients ≥0.8, and 32.6% with 1.0. Mean BCVA achieved was 0.94 (SD: 0.10). 
Mean preoperatory astigmatism was –2.25 diopters (D) (SD: 0.78), and mean postoperative 
astigmatism was -0.32 D (SD: 0.56), with significant differences between both groups 
(p<0.001). Model-specific mean residual astigmatism was –0.1 D for T3, –0.27 D for T4 and 
–0.43 D for T5, without significant differences between the three models (p=0.483). Mean 
IOL-axis rotation grade was 3.87±3.25 degrees, with 91.6% of implanted lens within 10° of 
predicted axis.
Discussion: T3, T4 and T5 Acrysof® Toric intraocular lenses can correct preoperative 
astigmatism with a high success rate in terms of UCVA, and residual postoperative 
astigmatism, with minimum IOL-rotation grade at 2 months follow-up period.
© 2010 Sociedad Española de Oftalmología. Published by Elsevier España, S.L. 
All rights reserved.
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R E S U M E N
Propósito: Valorar los resultados a medio plazo del implante de lentes intraoculares tóricas 
Acrysof en 54 pacientes (54 ojos).
Método: Los parámetros analizados fueron mejor agudeza visual sin corrección (AVSC) y 
agudeza visual mejor corregida (AVMC), astigmatismo preoperatorio y residual postopera-
torio, y rotación de la lente globalmente y en cada modelo de lente intraocular empleado.
Resultados: A los 2 meses del seguimiento, la AVSC media total fue de 0,83 (DS: 0,14) Snellen, 
estando el 73,9% de ellos con AVSC ≥ 0,8 y el 32,6% en 1,0. La AVMC fue de 0,94 (DS: 0,10). 
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Introduction
Cataract surgery has evolved in the past decades to become 
a safe and comfortable surgery with excellent visual quality 
results for patients. Phacoemulsification and the development 
of new devices have shortened the surgical procedure down 
to a few minutes with minimum aggression for the patient 
eye and a comfortable post-surgery period. However, the 
continuous development of innovations and technical 
improvements is accompanied by higher demand for better 
results by patients as well as surgeons in an ongoing search 
for excellence for the final visual quality of cataract patients. 
The objective is not only to improve the patient’s vision but to 
achieve emmetropia without added optical correction as far 
as possible. To this end, presurgery diagnostic devices have 
been developed to perform an exact calculation of the most 
adequate intra-ocular lens for each patient as well as new 
lens and device designs for adapting their use according to 
the criteria of each surgeon.
Along this line, astigmatism has represented a problem for 
the traditional spherical lens implant, with several solutions 
being proposed. The use of arcuate corneal incisions and excimer 
laser refractive keratectomy have become the best options for 
resolving these cases for a number of years until the recent 
appearance of thoric IOLs. These lenses have demonstrated 
excellent results in multicentre clinical trials since being 
presented in 1998, and their use has become mainstream in 
recent years.1 This study analyses the results obtained in 54 
patients intervened in our centre with implant of Acrysof® thoric 
lenses (Alcon Laboratories, Inc., Fort Worth, Texas).
Method
Fifty-four patients (54 eyes) intervened in our centre between 
July 2008 and March 2009 were included in the study. The 
main inclusion criterion was pre-surgery keratometric 
astigmatism as per IOL-Master® (Carl Zeiss Meditec Inc., 
Dublin, CA, USA)≥1.00. The spherical power of the lens was 
calculated with IOL-Master® with constant A optimised 
for this biometer (118.72), and keratometric values K1 and 
K2 what input to the Acrysof Toric Calculator® software 
(www.acrysoftoriccalculator.com, Alcon Laboratories Inc, 
Fort Worth, TX, USA) to determine the cylinder power (IOL 
model) and the exact pre-surgery IOL. The three lens models 
implanted were SN60T3, SN60T4 and SN60T5 for IOL plane 
cylinder correction of –1.50, –2.25 and –3.00 D, equivalent 
to –1.03, –1.55 and –2.06 D in corneal plane, respectively. 
Following the software IOL selection algorithm, the adequate 
IOL was determined for each patient and requested from the 
manufacturer. In the immediate presurgery, minutes before 
the intervention, the 0°–180° axis was marked with the patient 
at 90° from the floor to avoid torsion phenomena and, with 
the surgical fields in place, we marked the axis for the IOL 
calculated by the software using the 0°-180° axis as reference. 
All the surgical procedures, carried out by the same surgeon 
(JMM) with the Phaco-Chop technique went smoothly. The 
IOL implant was performed in the conventional manner 
with the Monarch II injector through a 2.4mm incision 
(fig. 1) and the IOL was centred placing its axis as calculated by 
the software. The irrigation-aspiration was performed softly 
to avoid lens rotation. The post-op was conventional, with 
topical administration of prednisolone-neomycin-polymixin 
B (Poly-pred®, Allergan Inc., Irvine, CA, USA) in descending 
pattern, without events in any of the 54 eyes. Two months 
after the intervention the NCVA and BCVA were determined, 
together with the post-op residual astigmatism and the final 
El astigmatismo medio preoperatorio fue de –2,25 dioptrías (D) (DS: 0,78), siendo el astig-
matismo medio postoperatorio total de –0,32 D (DS: 0,56), con diferencia estadísticamente 
significativa entre ambos grupos (p < 0,001). Desglosado por tipo de lente el astigmatismo 
fue –0,1 para las lentes T3, –0,27 D para las T4, y –0,43 para las T5, sin diferencias significa-
tivas entre los grupos estudiados (p = 0,483). La rotación media del eje de la LIO respecto al 
eje previsto fue de 3,87 ± 3,25 grados, con rotación menor a 10° en el 91,6% de las LIO im-
plantadas.
Discusión: Las lentes tóricas modelo Acrysof T3, T4 y T5 permiten corregir el astigmatismo 
preoperatorio con un porcentaje elevado de éxito en lo que a AVSC y astigmatismo residual 
postoperatorio se refiere, con un mínimo grado de rotación de la lente a los 2 meses.
© 2010 Sociedad Española de Oftalmología. Publicado por Elsevier España, S.L. 
Todos los derechos reservados.
Figure 1 – Lens injection with Monarch II cassette.
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IOL axis after midriasis (fig. 2) with phenylephrine eyedrops 
10% - tropicamide 1% (Alcon Cusí, El Masnou, Barcelona, 
Spain). The data were analysed with the SPSS 15.0 software 
(SPSS Inc, Chicago, IL, USA).
Results
Fifty-four eyes of 54 patients (n=54) were included in this study. 
The mean age was of 69.48 years (SD: 9.78), in a range of 51-
78 years. The distribution by sex was of 24 males (44.4%) and 
30 females (55.5%), and in what concerns the laterality of the 
intervened eyes, 23 were right eyes (42.59%) and 31 were left 
eyes (57.40%). All the included eyes completed the post surgery 
period without events. Eight patients were excluded due to 
baseline pathologies involving significant visual limitation: 
three had diabetic macular edema, two had advanced ARMD, 
2 had amblyopia and 1 venous branch thrombosis. As regards 
the remaining 46 eyes, the results were as follows (table 1): 
the mean total NCVA was of 0.83 (SD: 0.14) Snellen, in 73.9% 
of cases, it remained equal to or above 0.8, with 32.6% of the 
sample reaching the unit (1.0) (fig. 3). With optical correction, 
Figure 2 – Annotation of the post surgery lens axis, showing the points at both sides of the lens indicating its axis. Detail of 
slit lamp to measure final axis (25 degrees).
Figure 3 – Post surgery uncorrected visual acuity.
Figure 4 – Visual acuity with post surgery correction.
N
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Uncorr. VA (Snellen)
Corr. VA (Snellen)
Uncorr. VA
Corr. VA
 Unc VA Corr VA Preop Astig. Postop Astig.
No. of eyes 46 46 46 46
Mean 0.835 0.941 −2.2545 −0.3259
Typ. Dev. 0.1494 0.0977 0.78044 0.52097
Mean post surgery visual acuity (with and without optical correction) 
and mean astigmatism pre-surgery and two months post-surgery 
(n:46. Mean, Typical Deviation).
Table 1 – Visual equity and astigmatism 2 months post 
surgery
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the mean corrected visual acuity was of 0.94 (SD: 0.10) (fig. 4). 
The presurgery astigmatism correction was significant, with 
the mean value prior to surgery being of –2.25 (CI 95%: –2.48/ 
–2.02) while the post surgery mean total astigmatism was of 
–0.32 (CI 95%:–0.48/–0.15) (p<0.001).
After analysing the results per lens model, residual 
astigmatism for IOL model SN60T3 (n=11) was of –0.10 D, for 
SN60T4 (n=14) was of -0.27 D and for SN60T5 (n=21) was of 
–0.43 D, without statistical significance between any of the 
groups (p=0.483). The mean rotation against the calculated 
axis was of 3.87±3.25 degrees, without differences against 
the implanted IOL model, and 91.6% of the IOL exhibited a 
rotation of <10% from the calculated axis.
Discussion
The results obtained in our study match those of previously 
published series. The clinical trial carried out by the US Food 
& Drug Administration (FDA) in 2005, prior to the marketing of 
Acrysof® lenses, obtained 66% of patients with thoric IOL with 
NCVA≥ 0.8 at month six, similar to our 73.9%.1 The different 
sample size could explain the difference (n=250; n=46) 
between both results. The lens implantation did not depart 
from the standard injection procedure of common lenses, 
with the main differences between the published studies 
being in the determination of the pre-op K values and the 
0°-180° axis marking system. Several authors have utilized 
IOL Master in in their studies, although others have utilized 
systems such as Orbscan II (Bausch & Lomb, Rochester, NY, 
USA) or conventional keratometres to obtain the K values.2-4 
In what concerns the determination of the 0°-180° axis, the 
system utilized by the FDA and the authors was dermographic 
marking with slit lamp while in this study the Elies marker 
was utilized (E. Janach, Como, Italy). The results of these 
studies in what concerns the lens rotation degree are slightly 
lower than our 3.87°±3.25 values, varying in a range of 2.2° to 
3.75°, which is quite consistent with our data. The percentage 
of patients with IOL rotation <10° on two similar to our 91.6%, 
varying between 96.7 and 100%.1-5
In conclusion, Acrysof® T3, T4 and T5 thoric lens implants 
allow the correction of presurgery astigmatism with a high 
percentage of success in what concerns NCVA and residual 
postsurgery astigmatism, with a minimum degree of lens axis 
rotation after 2-6 months according to the published series.1-6 
The minor of modification of the surgical procedure and a 
broad dissemination of the necessary presurgery diagnostic 
devices, many of which are mainstream, lead us to consider 
a higher degree of utilization of this type of lenses in the mid 
term for patients with significant presurgery astigmatism 
intervened for cataracts.
R E F E R E N C E S
1. Horn JD. Status of toric intraocular lenses. Curr Opin 
Ophthalmol. 2007;18:58–61.
2. Bauer NJ, de Vries NE, Webers CA, Hendrikse F, Nuijts RM. 
Astigmatism management in cataract surgery with the 
AcrySof toric intraocular lens. J Cataract Refract Surg. 
2008;34:1483–8.
3. Mendicute J, Irigoyen C, Aramberri J, Ondarra A, Montés-Micó 
R. Foldable toric intraocular lens for astigmatism correction  
in cataract patients. J Cataract Refract Surg. 2008;34:601–7.
4. Zuberbuhler B, Signer T, Gale R, Haefliger E. Rotational stability 
of the AcrySof SA60TT toric intraocular lenses: a cohort study. 
BMC Ophthalmol. 2008;8:8.
5. Chang DF. Comparative rotational stability of single-piece 
open-loop acrylic and plate-haptic silicone toric intraocular 
lenses. J Cataract Refract Surg. 2008;34:1842–7.
6. Ruiz-Mesa R, Carrasco-Sánchez D, Díaz-Álvarez SB, Ruiz-
Mateos MA, Ferrer-Blasco T, Montés-Micó R. Refractive lens 
exchange with foldable toric intraocular lens. Am J 
Ophthalmol. 2009;147:990–6.
Document downloaded from http://www.elsevier.es, day 01/06/2012. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
